Pulmotect Inc.
Synthetic inhaled drug prevents pneumonia in cancer patients
This article was originally published in Start Up
Executive Summary
Pulmotect Inc. is developing a synthetic inhaled drug to prevent pneumonia in cancer patients. Its lead candidate PUL-042 is a broad-spectrum, immune stimulant with a unique formulation that targets the epithelial cells that line the airways.
You may also be interested in...
Pulmotect Seeks Quick-To-Market Path For Rapid-Acting Respiratory Drug
Selected by NIH and NSF for the Innovation Zone at BIO 2017, the Houston biotech's synthetic broad-spectrum drug has shown activity in animal models against every pathogen tested. Pulmotect hopes PUL-042 can prevent exacerbations in COPD patients who develop upper respiratory infections.
Vagisil Marketer Combe Enters Personal Lubricant Market With BioFilm Acquisition
Vagisil and BioFilm’s Astroglide “demonstrate very high levels of brand awareness, brand loyalty, and repeat purchase, and continue to attract new and younger consumers into the category,” firms say.
US Health And Wellness Launches: Perrigo, Lightbody, Nature’s Bounty, PLT, Healthycell, More
Nicotine mint lozenge approval for Perrigo; Lightbody for digital vision health; PLT has broad-spectrum immune health ingredient; Souvenaid for stronger synapses; Kinesiology tape for cellular oxygenation; Healthycell joint health and mobility gel; Nature’s Bounty Optimal Solutions hair, metabolism supplements; and Perricone extends vitamin c ester line.